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Unusual clinical course
Flecainide is a class Ic antiarrhythmic agent used in the treatment of supraventricular and ventricular arrhythmias. It is associated with a potent adverse eﬀect proﬁle; however, the eﬀects of ﬂecainide toxicity in the setting of a pacemaker have not been well described. We describe a unique case of ﬂecainide toxicity secondary
to acute kidney injury in the setting of a dual-chamber pacemaker, resulting in ventricular capture latency and
intermittent failure to capture.
The patient was a 91-year-old female with a history of atrial ﬁbrillation maintained in sinus rhythm on ﬂecainide, who presented complaining of purple visual disturbances and syncope. She was found to be hypotensive and bradycardic, with a heart rate between 30 to 40 beats per minute. Lab work was notable for creatinine
at 2.12 mg/dL. A 12-lead ECG demonstrated atrial and ventricular pacing with severely widened QRS complex
and a signiﬁcant latency between the pacemaker ventricular spike and the ventricular capture. The pacemaker
was interrogated, revealing a signiﬁcant increase in ventricular threshold from 0.75 V at 0.5 ms at baseline to
5.0 V at 1 ms to obtain consistent capture. After multiple boluses of IV sodium bicarbonate, the QRS acutely
narrowed, latency interval improved, and consistent pacing capture was achieved. The ﬂecainide level drawn
on arrival was 3.09 mcg/mL.
Flecainide increases the ventricular capture threshold for pacemakers. Toxicity in these patients may present
with pacemaker ventricular capture latency or failure to capture.
Acute Kidney Injury • Drug-Related Side Eﬀects and Adverse Reactions • Flecainide •
Pacemaker, Artiﬁcia
https://www.amjcaserep.com/abstract/index/idArt/916370
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Background
Flecainide is a Vaughan-Williams class Ic antiarrhythmic agent
used most commonly in the treatment of atrial ﬁbrillation,
atrial ﬂutter, and supraventricular and ventricular arrhythmias
in patients without known structural or ischemic cardiac disease [1,2]. As a class Ic agent, its primary mechanism of action
is blockade of fast sodium channels, resulting in a reduction
in myocardial conduction velocity and a negative inotropic effect on the myocardium. Its primary action in atrial tissue is
to prolong the eﬀective refractory period (ERP), demonstrating use-dependence, resulting in a more pronounced eﬀect
as the heart rate increases [3]. Flecainide has a narrow therapeutic window and a highly variable plasma half-life in the
setting of renal dysfunction. A mortality rate of 10–25% has
been reported with class Ic antiarrhythmic agent toxicity [4].
Although ﬂecainide toxicity is described in the literature on
acute kidney injury, there is a paucity of literature on the acute
presentation of ﬂecainide toxicity in the setting of a cardiac
pacemaker [5]. We describe a case of ﬂecainide toxicity secondary to acute kidney injury in the setting of dual-chamber
pacing, resulting in ventricular capture latency and intermittent failure to capture [6].

Case Report
The patient was a 91-year-old female with a history of paroxysmal atrial ﬁbrillation maintained in normal sinus rhythm on
ﬂecainide for more than 3 years. She also had sick sinus syndrome, with a dual-chamber pacemaker placed many years
prior, COPD, and heart failure with preserved ejection fraction. The patient presented for the ﬁrst time to the Emergency
Department (ED) complaining of nausea, lightheadedness, and
generalized weakness. The patient’s medication list was notable for the use of ﬂecainide 100 mg BID and metoprolol tartrate 50 mg BID. A recent transthoracic echocardiogram had
been performed a few months prior and had demonstrated
a normal ejection fraction, concentric left ventricular hypertrophy, and biatrial enlargement. The patient had recently undergone a total right knee replacement for degenerative joint
disease 4 weeks prior, and post-operatively the patient had developed these symptoms along with poor oral intake. The patient’s creatinine was noted to be elevated at 2.09 compared
to her baseline normal renal function. The patient was brieﬂy
admitted for acute kidney injury, re-hydrated with intravenous
ﬂuids, and discharged home without change in medications.
A few days later, the patient developed worsening fatigue and
lightheadedness with several episodes of syncope. She also
reported new visual disturbances with purple discoloration.
She presented again to the ED and was found to be hypotensive, tachypneic, mildly encephalopathic, and bradycardic
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with a heart rate of 30–40 beat per minute (bpm). A 12-lead
ECG demonstrated atrial and ventricular pacing with severely
widened QRS complex (QRS duration >200 ms) with a significantly latency between the pacemaker ventricular spike and
the ventricular capture. Metabolic studies were remarkable
for an ongoing elevation in creatinine at 2.12 with a GFR of
23 mL/min per 1.73 m2 and a lactate of 3.8 mmol/L with a potassium level at the upper limit of normal.
The patient’s dual-chamber pacemaker was emergently interrogated and found to be intermittently capturing in the ventricle. The ventricular threshold during device interrogation
indeed revealed a signiﬁcant increase from 0.75 V at 0.5 ms
at baseline to 5.0 V at 1 ms to obtain consistent capture,
even though a signiﬁcant latency persisted, as noted earlier
(Figure 1A). The patient was in complete heart block with no
ventricular escape, as demonstrated by the pacemaker intracardiac electrograms (Figure 2). Due to concern for suspected
ﬂecainide toxicity, she was given IV sodium bicarbonate and
a norepinephrine drip was started for initial hemodynamic support. After multiple boluses of IV sodium bicarbonate, the QRS
acutely narrowed, pacemaker latency interval improved, and
consistent pacing capture was achieved, although the paced
QRS remained abnormally prolonged (Figure 1B). The patient’s
cardiogenic shock secondary to bradycardia rapidly resolved.
Two days later, the paced QRS complex duration became narrower, similar to baseline (Figure 1C).
The ﬂecainide level drawn on arrival was 3.09 mcg/mL (reference range: 0.20–0.99 mcg/mL). A few days later, the intrinsic
atrioventricular conduction resumed. The electrolytes remained
in the normal range throughout the hospitalization. The patient’s acute kidney injury resolved and she was discharged
home. Flecainide was discontinued and the patient was continued on metoprolol tartrate for control of her atrial ﬁbrillation.

Discussion
We describe a case of a patient with a pacemaker who presented with ﬂecainide toxicity, in cardiogenic shock, with unstable bradycardia, and increased ventricular threshold and latency, leading to intermittent ventricular capture. Flecainide
has a potent adverse eﬀect proﬁle. The medication has a steep
dose-response curve and has been recognized as having a narrow therapeutic index [7]. Flecainide toxicity can result in nausea, vomiting, visual disturbances, and seizure [8]. In line with
this, our patient presented with nausea, fatigue, pre-syncope,
and visual disturbances. Like other antiarrhythmic agents, ﬂecainide has pro-arrhythmic properties, particularly at serum
levels greater than >1 mcg/mL and in patients with structural or ischemic cardiac disease [9]. Along with dose-dependent prolongation of the PR interval and widening of the QRS
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Figure 1. (A) 12-lead ECG performed after the
pacemaker was switched into VVI
mode at a pacing threshold of 5 mV
at 1 ms. Note the impressive latency
between the ventricular spike and
the ventricular depolarization and the
QRS duration above 200 ms. (B) 12lead ECG performed after treatment
with intravenous sodium bicarbonate,
demonstrating improvement of the
QRS duration and disappearance of
the latency interval. (C) 12-lead ECG
performed a day later, demonstrating
a ventricular paced rhythm with a QRS
narrower than that before ECG.

A

B

C

Figure 2. Intracardiac electrograms from the
initial pacemaker interrogation,
demonstrating no ventricular escape
at 40 bpm.
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complex, it has been reported that ventricular tachyarrhythmia, high-grade AV block, and bundle branch block are associated with ﬂecainide toxicity [8].
In our patient, the QRS complex was found to be severely widened on presentation, with a duration greater than 200 ms
and intermittent ventricular capture due to increased threshold. Flecainide toxicity results in rate-dependent QRS complex
widening by competitive inhibition of the Nav1.5 cardiac sodium channels, which results in a slowing of the phase 0 portion of the cardiac action potential [10].
A unique feature of this case is a dual-chamber pacemaker patient becoming pacemaker-dependent, with acute ﬂecainide
toxicity, and subsequently developing syncope due to ventricular capture latency and intermittent failure to capture. It has
been demonstrated that ﬂecainide can increase the ventricular
capture threshold for pacemakers, and patients at therapeutic
doses may require pacemaker setting adjustment when initiating ﬂecainide [11]. However, pacemaker failure to capture
in the setting of acute ﬂecainide toxicity has seldom been reported in the literature [5]. Our case also demonstrates a prolonged pacemaker latency interval in the setting of ﬂecainide
toxicity and subsequent rapid improvement in latency interval
after treatment with intravenous sodium bicarbonate, which
has not been previously reported. Along with elevated capture
thresholds, the ECG ﬁndings in this case were the result of the
device attempting to pace while the myocardium was in an
extended refractory period secondary to ﬂecainide. The intrinsic function of the device itself was normal. Adjustment of the
pacemaker settings to optimize pacing capture and prompt recognition that this was not “device failure” were important in
rapid resolution and minimization of morbidity in this patient.
Sodium bicarbonate is a well described therapy for ﬂecainide
toxicity. It has been demonstrated that both alkalization and
increased sodium concentration reverse ﬂecainide eﬀects on
Purkinje ﬁbers in animal models. This may be caused by accelerating ﬂecainide molecule dissociation from the sodium
channel receptor and by competitive inhibition, but the mechanism is not fully understood [12]. In our patient, prompt sodium bicarbonate administration resulted in rapid resolution of
the patient’s device failure to capture and cardiogenic shock.
Cardiac pacing has previously been described as a treatment
for ﬂecainide toxicity [13]. While it may be helpful when patients present with complete heart block, our case and other
cases described in the literature suggest that cardiac pacing
may be of minimal beneﬁt when the predominant issue is QRS
widening [14,15]. Acidiﬁcation of the urine has been shown to
increase urinary excretion of ﬂecainide, but there is little data
available on its clinical role in the setting of ﬂecainide toxicity,
and it was not pursued in the treatment of this patient [16].
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In the patient described, the etiology of ﬂecainide toxicity was
an acute kidney injury, which has been recognized as a common trigger. Flecainide is eliminated from the body by renal
excretion and the hepatic cytochrome P450 CYP2D6 enzyme.
The primary elimination mechanism is renal excretion and,
in the setting of normal renal function, 80–90% of the drug is
excreted into the urine [17]. In a patient with intact renal and
hepatic function, the medication’s plasma half-life is approximately 12–26 hours. However, studies have demonstrated that
the medication has a highly variable plasma half-life in the setting of renal dysfunction, and its usage requires caution and
dose adjustment in these circumstances [18]. An initial maximum oral dosage of 100 mg daily is typically recommended in
patients with moderate to severe renal failure (creatinine clearance <35 ml/min) [19]. Importantly, ﬂecainide cannot be removed with the use of hemodialysis. Furthermore, lower doses
should be considered in elderly patients, as in our case. Some
authors recommend altogether avoiding class I antiarrhythmic agents in very elderly patients due to their adverse eﬀect
proﬁle [20]. Flecainide particularly must be used with caution
in these patients due to the high probability of undiagnosed
coronary artery disease. Flecainide also has a known negative inotropic eﬀect and has been associated with increased
mortality in heart failure patients, particularly among patients
with heart failure with reduced ejection fraction [21]. Although
data are scarce regarding the use of ﬂecainide in patients with
heart failure with preserved ejection fraction, we believe ﬂecainide should be used with caution in these patients as well.

Conclusions
Flecainide is a class Ic antiarrhythmic agent with a narrow
therapeutic index and a potent adverse eﬀect proﬁle. Our report describes a unique case of ﬂecainide toxicity in a pacemaker-dependent patient. This case illustrates several important points regarding the treatment of patients with ﬂecainide
toxicity. When treating patients that have renal dysfunction
and older patients with ﬂecainide, physicians should exercise
caution. Patients with acute kidney injury should have their
medication discontinued or at least reduced until resolution.
Particular care should be practiced when treating patients on
ﬂecainide, even when they are not pacemaker-dependent, as it
is associated with the risk of iatrogenic complete heart block
and risk of pacemaker failure to capture due to elevated myocardial capture thresholds. This could be more dramatic for patients that are pacemaker-dependent. Sodium bicarbonate is
an eﬀective therapy for ﬂecainide toxicity.
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